124 related articles for article (PubMed ID: 18566241)
1. Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.
Morgillo F; Martinelli E; Troiani T; Laus G; Pepe S; Gridelli C; Ciardiello F
Mol Cancer Ther; 2008 Jun; 7(6):1698-707. PubMed ID: 18566241
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.
Tekle C; Giovannetti E; Sigmond J; Graff JR; Smid K; Peters GJ
Br J Cancer; 2008 Sep; 99(5):750-9. PubMed ID: 18728666
[TBL] [Abstract][Full Text] [Related]
3. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
[TBL] [Abstract][Full Text] [Related]
4. Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine.
Jian W; Yamashita H; Levitt JM; Lerner SP; Sonpavde G
Mol Cancer Ther; 2009 Jul; 8(7):1772-8. PubMed ID: 19509273
[TBL] [Abstract][Full Text] [Related]
5. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
Graff JR; McNulty AM; Hanna KR; Konicek BW; Lynch RL; Bailey SN; Banks C; Capen A; Goode R; Lewis JE; Sams L; Huss KL; Campbell RM; Iversen PW; Neubauer BL; Brown TJ; Musib L; Geeganage S; Thornton D
Cancer Res; 2005 Aug; 65(16):7462-9. PubMed ID: 16103100
[TBL] [Abstract][Full Text] [Related]
6. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.
Rizvi MA; Ghias K; Davies KM; Ma C; Weinberg F; Munshi HG; Krett NL; Rosen ST
Mol Cancer Ther; 2006 Jul; 5(7):1783-9. PubMed ID: 16891464
[TBL] [Abstract][Full Text] [Related]
7. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS
PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748
[TBL] [Abstract][Full Text] [Related]
8. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer.
Lee SH; Chen T; Zhou J; Hofmann J; Bepler G
Clin Lung Cancer; 2010 May; 11(3):169-75. PubMed ID: 20439192
[TBL] [Abstract][Full Text] [Related]
10. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway.
Querfeld C; Rizvi MA; Kuzel TM; Guitart J; Rademaker A; Sabharwal SS; Krett NL; Rosen ST
J Invest Dermatol; 2006 Jul; 126(7):1641-7. PubMed ID: 16645590
[TBL] [Abstract][Full Text] [Related]
11. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.
Neri A; Marmiroli S; Tassone P; Lombardi L; Nobili L; Verdelli D; Civallero M; Cosenza M; Bertacchini J; Federico M; De Pol A; Deliliers GL; Sacchi S
Leuk Lymphoma; 2008 Jul; 49(7):1374-83. PubMed ID: 18452078
[TBL] [Abstract][Full Text] [Related]
12. Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells.
Serova M; Astorgues-Xerri L; Bieche I; Albert S; Vidaud M; Benhadji KA; Emami S; Vidaud D; Hammel P; Theou-Anton N; Gespach C; Faivre S; Raymond E
Mol Cancer Ther; 2010 May; 9(5):1308-17. PubMed ID: 20406951
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.
Del Bufalo D; Desideri M; De Luca T; Di Martile M; Gabellini C; Monica V; Busso S; Eramo A; De Maria R; Milella M; Trisciuoglio D
Mol Cancer; 2014 Oct; 13():230. PubMed ID: 25301686
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC).
Giovannetti E; Honeywell R; Hanauske AR; Tekle C; Kuenen B; Sigmond J; Giaccone G; Peters GJ
Curr Drug Targets; 2010 Jan; 11(1):12-28. PubMed ID: 19839931
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in-vitro [corrected] soft-agar cloning experiments.
Hanauske AR; Oberschmidt O; Hanauske-Abel H; Lahn MM; Eismann U
Invest New Drugs; 2007 Jun; 25(3):205-10. PubMed ID: 17347872
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
Vogl UM; Berger W; Micksche M; Pirker C; Lamm W; Pichelmeyer O; Zielinski CC; Schmidinger M
Cancer Lett; 2009 May; 277(2):218-26. PubMed ID: 19171421
[TBL] [Abstract][Full Text] [Related]
18. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
[TBL] [Abstract][Full Text] [Related]
19. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells.
Li T; Ling YH; Goldman ID; Perez-Soler R
Clin Cancer Res; 2007 Jun; 13(11):3413-22. PubMed ID: 17545550
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer.
Tanai C; Yamamoto N; Ohe Y; Takahashi T; Kunitoh H; Murakami H; Yamamoto N; Nakamura Y; Nokihara H; Shukuya T; Baldwin JR; Koshiji M; Tamura T
J Thorac Oncol; 2010 Jul; 5(7):1068-74. PubMed ID: 20453691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
